{"id":"ropinirole-l-dopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Hallucinations"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL1200411","moleculeType":"Small molecule","molecularWeight":"296.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets Parkinson's disease by dual mechanisms: ropinirole directly activates dopamine receptors to compensate for dopamine loss, while L-dopa (levodopa) is converted to dopamine in the brain to further restore dopaminergic neurotransmission. The combination provides complementary dopaminergic replacement therapy to alleviate motor symptoms of Parkinson's disease.","oneSentence":"Ropinirole is a dopamine D2/D3 receptor agonist that mimics dopamine signaling, while L-dopa is a dopamine precursor that increases dopamine levels in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:38.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT03250117","phase":"PHASE1, PHASE2","title":"Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT01154166","phase":"PHASE3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-15","conditions":"Parkinson Disease","enrollment":347},{"nctId":"NCT01494532","phase":"PHASE4","title":"A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-02","conditions":"Parkinson Disease","enrollment":352},{"nctId":"NCT00331149","phase":"PHASE3","title":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-20","conditions":"Parkinson Disease","enrollment":343},{"nctId":"NCT00381472","phase":"PHASE3","title":"Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Parkinson Disease","enrollment":393},{"nctId":"NCT00363727","phase":"PHASE3","title":"Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12","conditions":"Parkinson's Disease, Parkinson Disease, Dyskinesias","enrollment":209},{"nctId":"NCT00823836","phase":"PHASE3","title":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":302},{"nctId":"NCT01628926","phase":"PHASE3","title":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-06","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT00485069","phase":"PHASE4","title":"REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ropinirole/L-dopa","genericName":"ropinirole/L-dopa","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole is a small molecule that acts as a D2-like dopamine receptor agonist. It is used to treat conditions such as Parkinson's disease and dyskinesias, often in combination with L-dopa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}